What is a contract research organization (CRO)? The complete guide for clinical trial sponsors
Behind almost every major drug approval in recent decades, there is a contract research organization working in the background. Yet for many professionals entering clinical research, and even some sponsors new to outsourcing, the role, structure, and responsibilities of a contract research organization remain surprisingly unclear.
This guide answers every question you are likely to have: what a contract research organization is, what one actually does in a clinical trial, how the sponsor-CRO relationship is governed under ICH GCP, and how to choose the right one for your study. Whether you are a sponsor considering outsourcing for the first time or a clinical research professional wanting to understand the broader ecosystem, this is your definitive reference.
A contract research organization (CRO) is a company that provides clinical research services to sponsors on a contractual basis. These services can range from a single function, such as biostatistics or regulatory writing, to the complete management of a clinical trial from protocol development to final regulatory submission. Under ICH GCP E6 R3, a sponsor may transfer any or all of its trial-related duties and functions to a CRO, but cannot transfer ultimate responsibility for the quality and integrity of the trial.
While most commercial CRO engagements involve pharmaceutical and biotechnology companies, contract research organizations also support academic research institutions, government agencies such as the National Institutes of Health (NIH), and non-profit organisations conducting clinical trials.
What is a contract research organization?
What is a CRO in clinical research?
A contract research organization, commonly abbreviated to CRO, is a private company that offers a broad spectrum of research and development services to the pharmaceutical, biotechnology, and medical device industries. In the context of clinical trials, a contract research organization acts as an outsourced partner to the trial sponsor, taking on defined responsibilities for the planning, conduct, monitoring, data management, and reporting of clinical studies.
The CRO model emerged in the 1970s and 1980s as pharmaceutical companies began to recognise that maintaining large internal clinical operations teams was costly and inefficient, particularly for sponsors who did not run continuous programmes of trials. Outsourcing to a contract research organization allowed sponsors to access specialised expertise and global operational capacity on a study-by-study basis, without the overhead of permanent infrastructure.
Today, the contract research organization industry is a core pillar of the global clinical research ecosystem. The largest CROs, organizations such as IQVIA, Labcorp Drug Development, Syneos Health, PPD, and Parexel, operate across more than 100 countries and employ tens of thousands of clinical research professionals. Smaller, niche CROs serve specific therapeutic areas, geographic regions, or early-phase development needs. Together, they conduct the majority of the world’s sponsored clinical trials.
Contract research organization vs clinical research organization: is there a difference?
Both, a contract research organization and a clinical research organization, use the acronym CRO. A contract research organization, in its broadest sense, covers pre-clinical services including pharmacology, toxicology, and formulation development; a clinical research organization specifically manages clinical trial conduct; in practice, many large CROs do both; the terms are often used interchangeably in industry but the NIH and FDA documentation maintains the distinction.
What is the difference between a CRO and a sponsor?
The sponsor is the individual, company, institution, or organization that takes responsibility for the initiation, management, and financing of a clinical trial. In most commercial drug development programmes, the sponsor is the pharmaceutical or biotechnology company that owns the investigational product.
A contract research organization is not a sponsor. It is a service provider engaged by the sponsor to carry out defined functions. The critical distinction, and the one that carries the most weight under GCP, is that while a sponsor can delegate trial activities to a contract research organization, the sponsor retains ultimate responsibility for the quality and integrity of the trial. This is not a technicality. It means that if a CRO makes a serious error, the sponsor is still accountable to the regulatory authority for that error having occurred.
This principle is one of the most important concepts in the sponsor-CRO relationship and is examined in detail in the section on CRO vs sponsor responsibilities below.
What does CRO stand for and are there other names?
CRO stands for contract research organization. The term is used universally across the pharmaceutical, biotechnology, and medical device industries. You may occasionally encounter the term Contract Research Organization (using the British spelling) or the broader term Clinical Research Organization, both refer to the same type of entity. Some organizations prefer the term clinical service organization (CSO) or clinical development partner, but these are minority usages. Contract research organization remains the standard industry term and the one used in regulatory guidance.
Pre-clinical research services
Most big CROs also cover pre-clinical CRO services, as IND-enabling studies, pharmacology and toxicology testing, bioanalytical method development, pharmacokinetics and pharmacodynamics studies, stability testing, or formulation development.
Many sponsors first engage a CRO for pre-clinical work before moving into clinical phases.
What does a contract research organization do?
The full range of CRO services in clinical trials
A full-service contract research organization can manage every aspect of a clinical trial from the earliest stages of development planning through to regulatory submission. The scope of services offered by a contract research organization typically includes the following.
Clinical operations and site management: These functions are the core of what most people think of when they think of a CRO. It includes site identification and feasibility assessment, site initiation, patient recruitment support, clinical monitoring (on-site and remote), and site close-out activities. The clinical research associates (CRAs) employed by a contract research organization are the primary point of contact between the sponsor and the investigator sites during the conduct of the trial.
Regulatory affairs: Contract research organizations with regulatory capabilities support sponsors in preparing and submitting regulatory documents, including Investigational New Drug (IND) applications, Clinical Trial Authorisation (CTA) applications, and eventually marketing authorisation applications (MAAs) or New Drug Applications (NDAs). They may also manage interactions with regulatory authorities on the sponsor’s behalf.
Data management: Clinical data management services include the design and validation of electronic data capture (EDC) systems, database build and testing, data cleaning, query management, and database lock. Reliable data management is the foundation of regulatory submission; without clean, ALCOA++-compliant data, trial results cannot be accepted by regulatory authorities.
Biostatistics: The contract research organization’s biostatistics team develops the statistical analysis plan (SAP), performs the primary statistical analyses of trial data, and produces the output tables, listings, and figures (TLFs) that populate the clinical study report.
Medical writing: CROs provide medical writers who produce essential regulatory documents, including protocols, investigator brochures, clinical study reports (CSRs), and summaries of clinical safety and efficacy for regulatory submissions.
Pharmacovigilance and safety: Contract research organizations with pharmacovigilance capabilities manage the collection, processing, and reporting of adverse events and serious adverse events (SAEs) during the trial. They may also manage the expedited reporting of suspected unexpected serious adverse reactions (SUSARs) to regulatory authorities and ethics committees.
Central laboratory services: Some contract research organizations operate or partner with central laboratories that process and analyse biological samples from trial participants, blood, urine, tissue biopsies, and other specimens — providing standardised results across all sites in a multi-centre trial.
Quality assurance. CRO QA teams conduct internal audits of trial conduct, data, and processes to verify GCP compliance before a regulatory inspection occurs.
Post-marketing surveillance and Phase IV: CRO involvement does not end at regulatory approval; pharmacovigilance, risk management, and real-world evidence studies are often conducted by CROs after a product reaches the market.
What types of contract research organization exist?
Not all contract research organizations offer the same breadth of services, and understanding the different types is important when selecting a partner.
Full-service CROs offer end-to-end trial management across all phases of development. They have the internal capacity to manage every function from protocol development to regulatory submission. The largest global CROs fall into this category. They are suitable for sponsors conducting large Phase II, Phase III, or global multi-regional trials that require coordinated expertise across many disciplines and geographies.
Functional service provider (FSP) CROs offer specific functions rather than complete trial management. A sponsor might engage an FSP CRO solely for clinical monitoring, or solely for data management, while managing other functions internally or through different partners. This model gives sponsors more control and flexibility, and can be more cost-effective for organizations with strong internal capabilities in some areas.
Niche or specialist CROs focus on specific therapeutic areas, oncology, rare diseases, CNS, cardiovascular, or specific phases of development, particularly Phase I. Their expertise in a defined domain can be valuable when a sponsor requires deep therapeutic knowledge rather than broad operational capability.
Regional CROs operate in specific geographies and are particularly useful for sponsors who need to conduct trials in markets where a global CRO may lack local regulatory expertise, site relationships, or language capability.
How can a contract research organization help your clinical trial?
The case for outsourcing to a CRO
Sponsors choose to work with a contract research organization for a range of strategic and operational reasons.
Access to expertise: A contract research organization employs specialists across every discipline relevant to clinical trial conduct, regulatory affairs, biostatistics, data management, medical writing, pharmacovigilance, and clinical operations. For a small or mid-sized sponsor without deep internal teams, this access to assembled expertise would be impossible to replicate independently.
Global operational reach: Running a multi-regional trial requires relationships with investigator sites in dozens of countries, knowledge of local regulatory requirements, and the ability to manage monitoring, data collection, and safety reporting across multiple time zones and languages. An established contract research organization has this infrastructure ready to deploy.
Speed to market: A well-managed CRO partnership can compress development timelines significantly. CROs with established site networks can initiate sites faster, recruit participants more efficiently, and apply lessons from previous trials to anticipate and resolve operational problems before they cause delays.
Cost management: While engaging a contract research organization involves significant contractual investment, it eliminates the fixed overhead costs of maintaining a permanent internal clinical team. For sponsors who do not run continuous trial programmes, the variable cost model of outsourcing is more economical than building and sustaining internal infrastructure.
Risk distribution: A contract research organization with a strong quality management system and GCP compliance culture adds a layer of risk management to the sponsor’s programme. Experienced CROs have dedicated QA teams, established SOPs, and audit-ready documentation systems that reduce the probability of inspection failures.
What a contract research organization cannot do
A contract research organization can do a great deal, but sponsors need to understand what remains their responsibility regardless of the outsourcing arrangement.
The sponsor cannot outsource ultimate accountability. As noted above and as explicitly stated in ICH GCP E6 R3, the sponsor retains responsibility for the quality and integrity of the trial data, the safety of participants, and compliance with GCP, regardless of how comprehensively functions have been delegated to a contract research organization.
The sponsor also cannot outsource the obligation to oversee the CRO. ICH E6 R3 is explicit that the sponsor must establish a system to verify that the contract research organization is fulfilling its delegated responsibilities. A sponsor who hands over a trial to a CRO and disengages from oversight is not GCP-compliant, even if the CRO itself is performing well.
CRO vs sponsor responsibilities under ICH GCP
How ICH GCP E6 R3 governs the CRO relationship
The relationship between a sponsor and a contract research organization is governed by ICH GCP E6 R3, which sets out clear expectations for how responsibilities must be allocated, documented, and overseen. Understanding these requirements is essential for both parties.
ICH E6 R3 states that a sponsor may transfer any or all trial-related duties and functions to a contract research organization. However, the ultimate responsibility for the quality and integrity of the trial data always remains with the sponsor. This is a non-negotiable principle, no contract can transfer the sponsor’s GCP accountability to a CRO.
When a sponsor delegates functions to a contract research organization, all delegated responsibilities must be specified in a written agreement, typically a master service agreement (MSA) combined with study-specific work orders or statements of work (SOWs). This written agreement must clearly define which functions have been transferred, to what standard they must be performed, and how the sponsor will oversee the CRO’s performance of those functions.
Any functions not explicitly transferred in this written agreement remain the sponsor’s responsibility by default. This is a common source of dispute and compliance gaps, sponsors and CROs sometimes have different assumptions about who is responsible for a specific activity when it has not been clearly assigned in the contract.
ICH GCP E6 R3 — what the guideline says about CROs
Previously, ICH GCP R2 had specific sections (5.2.1 through 5.2.4) assigned to CROs’ responsibilities. Nonetheless, ICH GCP R3 removes the term CRO. It replaces it with the broader term “Services Provider”, and states the following:
- 10.2 Agreements should clearly define the roles, activities and responsibilities for the clinical trial and be documented appropriately. Where activities have been transferred or delegated to service providers, the responsibility for the conduct of the trial, including quality and integrity of the trial data, resides with the sponsor or investigator, respectively.
- 3.6.1 Agreements made by the sponsor with the investigator/institution, service providers and any other parties (e.g., independent data monitoring committee (IDMC), adjudication committee) involved with the clinical trial should be documented prior to initiating the activities.
- 3.6.2 Agreements should be updated when necessary to reflect significant changes in the activities transferred.
- 3.6.3 The sponsor should obtain the investigator’s/institution’s and, where applicable, service provider’s agreements:
- (a) To conduct the trial in accordance with the approved protocol and in compliance with GCP and applicable regulatory requirement(s);
- (b) To comply with procedures for data recording/reporting;
- (c) To retain the essential records for the required retention period in accordance with applicable regulatory requirements or until the sponsor informs the investigator/institution or, where applicable, the service provider that these records are no longer needed, whichever is longest;
- (d) To permit monitoring and auditing by sponsors, inspections by regulatory authorities (domestic and foreign) and, in accordance with applicable regulatory requirements, review by IRBs/IECs, including providing direct access to source records and facilities, including to those of service providers.
- 3.6.4 Any of the sponsor’s trial-related activities that are transferred to and assumed by a service provider should be documented in an agreement. The sponsor’s trial-related activities that are not specifically transferred to and assumed by a service provider are retained by the sponsor.
- 3.6.5 The sponsor should provide information to the investigator on any service provider identified by the sponsor to undertake any activities under the responsibility of the investigator. The responsibility for such activities remains with the investigator (see section 2.3.1).
- 3.6.6 A sponsor may transfer any or all of the sponsor’s trial-related activities to a service provider in accordance with applicable regulatory requirements; however, the ultimate responsibility for the sponsor’s trial-related activities, including protection of participants’ rights, safety and well-being and reliability of the trial data, resides with the sponsor. Any service provider used to perform clinical trial activities should implement appropriate quality management and report to the sponsor incidents that might have an impact on the safety of trial participants or/and trial results.
- 3.6.7 The sponsor is responsible for assessing the suitability of and selecting the service provider to ensure that they can adequately undertake the activities transferred to them. The sponsor should provide the service providers with the protocol where necessary as well as any other documents required for them to perform their activities.
- 3.6.8 The sponsor should have access to relevant information (e.g., SOPs and performance metrics) for selection and oversight of service providers.
- 3.6.9 The sponsor should ensure appropriate oversight of important trial-related activities that are transferred to service providers, including activities further subcontracted by the service provider.
For a full breakdown of how GCP structures oversight responsibilities across all trial roles, see our guide to principal investigator responsibilities under GCP.
Sponsor responsibilities that cannot be delegated to a CRO
Even in a full-service outsourcing arrangement, certain sponsor responsibilities cannot be transferred to a contract research organization.
The sponsor must retain oversight of the CRO’s performance. This means the sponsor must have a system in place, often managed by a sponsor-side clinical team or a dedicated oversight function, to review the CRO’s deliverables, monitor key performance indicators, conduct sponsor audits of the CRO, and escalate issues through a defined quality management process.
The sponsor must ensure that the trial is conducted in compliance with the approved protocol, applicable GCP guidelines, and local regulatory requirements. If the contract research organization conducts a monitoring visit and fails to identify a serious protocol deviation at a site, the sponsor remains accountable for that oversight failure.
The sponsor retains responsibility for all decisions regarding the continuation, modification, or termination of the trial based on safety data. A contract research organization may manage the pharmacovigilance function and generate safety reports, but the sponsor makes the ultimate decision on participant safety matters.
CRO responsibilities under ICH GCP
When a contract research organization accepts delegated functions from a sponsor, it takes on GCP obligations for those functions. The CRO must perform the delegated activities in compliance with ICH GCP, the agreed protocol, applicable SOPs, and all regulatory requirements. The CRO must also implement a quality management system that meets the standards expected by ICH E6 R3, including risk-based approaches to monitoring, proportionate documentation, and proactive identification of quality issues.
Under ICH E6 R3’s emphasis on quality by design, both the sponsor and the contract research organization are expected to collaborate in identifying Critical to Quality (CtQ) factors at the trial design stage, those elements of the protocol and operations that are most important to participant safety and the reliability of results. This collaborative quality planning approach represents a significant evolution from the R2 model, where the sponsor largely designed the trial and handed it to the CRO for execution. For a full breakdown of what changed between R2 and R3 across all areas of GCP, see our detailed comparison guide.
How to choose a contract research organization
Key factors in CRO selection
Selecting the right contract research organization is one of the most consequential decisions a sponsor makes in the lifecycle of a clinical programme. The wrong choice can result in recruitment delays, data quality problems, regulatory findings, and significant additional cost. The right choice can accelerate development timelines, improve data quality, and give the sponsor access to expertise they could not build internally.
The following criteria should anchor every CRO selection process.
Therapeutic area expertise: The most important single factor for most sponsors is whether the contract research organization has genuine experience in the relevant therapeutic area. This means not just familiarity with the general disease area, but specific experience with the patient population, the standard of care, the regulatory environment, and the types of endpoints being assessed. Ask the CRO to provide case studies from comparable studies, and ask to speak with the therapeutic lead who will be assigned to your programme, not just with the business development team.
Regulatory track record: Ask the contract research organization how many regulatory inspections their studies have undergone in the past three years, and what the outcomes were. A CRO with a strong inspection track record across FDA, EMA, and other major regulatory authorities is a meaningful indicator of operational quality. Be cautious of CROs that are reluctant to share this information.
Site network and recruitment capabilities: Patient recruitment is the most common cause of clinical trial delay. Evaluate the CRO’s established site relationships in your target geographies, their track record for meeting enrolment targets on comparable studies, and their strategy for accelerating recruitment if targets are missed.
Technology and data systems: Review the contract research organization’s electronic data capture (EDC), clinical trial management system (CTMS), and pharmacovigilance platforms. Ensure these systems are validated, compatible with your own infrastructure, and capable of meeting the data quality standards required by ICH E6 R3. Increasingly, sponsors should also evaluate the CRO’s capability for decentralised trial support, eConsent platforms, remote monitoring, and wearable data integration, given the direction of travel in ICH E6 R3.
Quality management system: Ask to review the CRO’s quality management framework, including how they identify and manage risks, how deviations and CAPAs are handled, and how they implement the quality-by-design principles of ICH E6 R3. A contract research organization that still operates with a purely reactive compliance model, finding and fixing problems rather than preventing them, is not aligned with current regulatory expectations.
Size and resource fit: The largest global CROs are not always the best fit. A small biotechnology sponsor running a single Phase II trial may receive more attentive service and better-matched seniority of staff from a mid-sized or niche CRO than from a full-service global organization where the study represents a small fraction of portfolio revenue.
Financial stability: CRO mergers, acquisitions, and financial difficulties are not uncommon in this industry. A contract research organization that is acquired mid-study, or that experiences financial instability, can create significant operational disruption. Assess the CRO’s financial health and ownership stability as part of due diligence.
The RFP and bid defence process
The standard process for CRO selection involves issuing a request for proposal (RFP) to a shortlist of candidate CROs. The RFP should provide enough detail about the study, protocol synopsis, target indication, geographic scope, timelines, and budget parameters, for the CRO to provide a meaningful operational and financial proposal.
Following receipt of proposals, sponsors typically invite the leading candidates to a bid defence meeting, a structured session in which the CRO presents their operational plan, introduces the team who will actually work on the study, and responds to detailed questions from the sponsor. The bid defence is the most valuable evaluation opportunity in the selection process. It reveals how the CRO thinks about problems, how they communicate, and whether the proposed team has genuine therapeutic knowledge or is relying on generic presentations.
Red flags in CRO selection
Certain signals during the selection process should prompt serious caution regardless of how competitive the financial proposal appears.
A contract research organization that introduces senior leaders during the bid defence but cannot confirm these individuals will be assigned to your study is a common source of disappointment. The quality of the team presented at bid defence is often not the quality of the team that executes the trial.
A CRO that proposes an unrealistically compressed timeline or an unusually low budget without clear justification for how these figures are achievable should be questioned carefully. Underpricing is a commercial strategy that frequently results in resource constraints during trial execution.
A contract research organization that is unable to provide references from sponsors who have run comparable studies, or that discourages direct contact with those references, is a meaningful negative signal.
Sponsor oversight of a contract research organization: what ICH E6 R3 requires
Building an effective oversight model
Sponsor oversight of the contract research organization is not optional under ICH GCP, it is a specific compliance obligation. ICH GCP E6 R3 requires the sponsor to implement a system to verify that the CRO is performing its delegated functions in accordance with GCP and the agreed protocol.
In practice, this means the sponsor must dedicate internal resources to CRO oversight, typically a clinical programme manager or alliance manager who maintains regular communication with the CRO, reviews key deliverables, tracks performance metrics, and escalates issues through an agreed governance structure.
The sponsor should also conduct periodic audits of the contract research organization. These are distinct from the CRO’s own internal quality audits. A sponsor audit assesses whether the CRO is performing as contracted and as required by GCP, and is an important independent check on CRO performance that regulators expect to see evidence of at inspection.
Key performance indicators for CRO oversight
Effective sponsor oversight typically tracks a defined set of key performance indicators (KPIs) for the contract research organization’s performance. Common KPIs include site activation timelines against plan, enrolment rate against projections, query resolution timelines, protocol deviation rates, serious adverse event reporting compliance, and monitoring visit completion against schedule. Where KPIs are trending negatively, the sponsor must engage with the CRO early, not wait for the deviation to become a regulatory finding.
Key takeaways
A contract research organization is far more than an outsourced vendor. In the modern clinical development landscape, the CRO is a strategic partner whose capabilities, quality culture, and regulatory track record directly influence whether a sponsor’s programme succeeds or fails.
The most important things to understand about the contract research organization model are these. The sponsor cannot outsource its GCP accountability, only its operational functions. The sponsor-CRO relationship must be governed by a written agreement that clearly defines every transferred responsibility. ICH E6 R3 places new demands on both sponsors and CROs to collaborate on quality planning from the trial design stage. Choosing the right contract research organization requires rigorous evaluation of therapeutic expertise, regulatory track record, technology capability, and team quality, not just financial comparison.
And finally: a contract research organization relationship managed well, with active sponsor oversight and genuine quality collaboration, is one of the most powerful accelerants available to a clinical development programme. Managed poorly, it is one of the most common causes of trial failure.
Conclusion
The contract research organization has become indispensable to modern clinical research. The scale, complexity, and regulatory demands of contemporary clinical trials make it virtually impossible for most sponsors, particularly smaller biotechnology and pharmaceutical companies, to conduct clinical development entirely with internal resources.
Understanding what a contract research organization is and what it does is essential knowledge for anyone working in clinical development. This knowledge is important not just for those in sponsor organizations, but also for investigators, site staff, regulators, and clinical research professionals across the ecosystem. The GCP framework governs the relationship between the contract research organization and the sponsor, highlighting the crucial aspects of compliance and quality in clinical trials.
ICH E6 R3 has made this relationship more structured, more quality-focused, and more demanding of active collaboration than at any previous point in the history of GCP. Sponsors who understand these requirements and choose, manage, and oversee their contract research organization accordingly are better positioned for inspection success, faster development timelines, and ultimately, the regulatory approvals that bring new treatments to patients.
Are your clinical research teams GCP-certified for the R3 era?
Whether you work for a sponsor, a contract research organization, or a clinical trial site, your understanding of ICH GCP E6 R3 directly determines the quality of the work you deliver and your value in the clinical research job market.
If you want to understand how the sponsor-CRO relationship is governed under GCP, how quality by design applies to your role, and what ICH E6 R3 requires at every level of the clinical trial ecosystem, our ICH GCP E6 R3 certification programme gives you exactly that knowledge, in a practical, accessible format that you can complete entirely online.
Start with our 2026 GCP certification guide if you are new to the topic, or go straight to our courses if you are ready to get certified.
Our courses are accredited by the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK) and approved by TransCelerate, making your certificate recognised by sponsors, CROs, and regulators worldwide.
Click here to get your ICH GCP certification today.
Already working at a CRO or sponsor and certified under R2? Our R3 update course covers the new quality by design requirements, proportionality principle, decentralised trial oversight, and everything else that has changed in the sponsor-CRO relationship under the new guidelines
FAQ: Contract research organization
What is a contract research organization in simple terms?
A contract research organization is a company hired by a pharmaceutical, biotechnology, or medical device sponsor to manage some or all of the activities involved in conducting a clinical trial. The CRO provides expertise, operational infrastructure, and global reach that many sponsors cannot maintain internally. The sponsor pays the CRO for these services under a formal written agreement, but retains ultimate GCP responsibility for the trial.
What does a CRO do in a clinical trial?
A contract research organization can perform a wide range of trial functions depending on what the sponsor has contracted for. These include clinical site management and monitoring, regulatory submissions, data management, biostatistics, medical writing, pharmacovigilance, central laboratory services, and quality assurance. A full-service CRO can manage an entire clinical programme from protocol design to regulatory submission.
What is the difference between a sponsor and a CRO?
The sponsor is the entity that owns the investigational product and takes overall responsibility for the trial. A contract research organization is a service provider engaged by the sponsor to perform defined trial functions. The sponsor retains ultimate GCP accountability regardless of how much has been outsourced to the CRO.
How do I choose the right contract research organization?
Key selection criteria include therapeutic area expertise, regulatory inspection track record, site network and recruitment capability, technology platforms, quality management system, financial stability, and size fit for your programme. The bid defence meeting, where the CRO presents the actual team assigned to your study, is the most important evaluation opportunity in the selection process.
What are the GCP requirements for the sponsor-CRO relationship?
ICH GCP E6 R3 requires that all delegated responsibilities be specified in a written agreement between the sponsor and the contract research organization. The sponsor must implement a system to oversee the CRO’s performance of those responsibilities, including periodic audits. Functions not explicitly delegated in the written agreement remain the sponsor’s responsibility. Under no circumstances can the sponsor transfer its ultimate GCP accountability to the CRO.
Can a CRO be held responsible for GCP violations?
A contract research organization that performs delegated functions takes on GCP obligations for those functions and can be subject to regulatory inspection. However, the sponsor also remains accountable for violations that occur within delegated CRO activities. Regulatory inspections of CRO operations have resulted in findings against both the CRO and the sponsor. Both parties share responsibility for ensuring delegated activities are performed to GCP standards.
What is a full-service CRO?
A full-service contract research organization offers end-to-end clinical trial management across all phases of development, from early clinical planning through regulatory submission. Full-service CROs have internal capabilities across clinical operations, regulatory affairs, data management, biostatistics, medical writing, and pharmacovigilance, allowing a sponsor to manage an entire programme through a single outsourcing partner.
What changed for CROs under ICH E6 R3?
ICH E6 R3 introduced several changes that directly affect how contract research organizations operate. These include the requirement to apply quality by design principles from the trial design stage, collaborating with sponsors to identify Critical to Quality factors. R3 also requires proportionate approaches to monitoring and oversight, stronger emphasis on participant comprehension in consent processes, and explicit acknowledgement of decentralised trial conduct. CROs must now demonstrate a proactive quality management culture, not just procedural compliance.
How does a sponsor oversee a CRO under GCP?
ICH E6 R3 requires the sponsor to implement a formal system for overseeing the CRO’s performance. In practice this includes regular performance reviews against agreed KPIs, review of monitoring reports and data quality metrics, periodic sponsor audits of the CRO, and a defined escalation process for issues identified during oversight. A sponsor who delegates to a CRO without maintaining active oversight is not GCP-compliant.
What is the difference between a full-service CRO and a functional service provider?
A full-service contract research organization manages all aspects of a clinical trial on behalf of the sponsor. A functional service provider (FSP) CRO performs a specific function, such as clinical monitoring or data management, while the sponsor manages other functions internally or through different providers. The FSP model offers more sponsor control and can be more cost-effective for organisations with strong internal capabilities in some areas.
What is the difference between a contract research organization and a clinical research organization?
Both terms use the acronym CRO. A contract research organization, in its broadest definition, covers both pre-clinical laboratory services and clinical trial management. A clinical research organization specifically refers to the subset that manages the conduct of clinical trials in humans. In practice, the terms are used interchangeably in most industry contexts, and many large CROs provide both pre-clinical and clinical services. The NIH and some regulatory documents maintain the distinction formally.
What is the difference between a CRO, a CMO, and a CDMO?
A contract research organization (CRO) manages research activities and clinical trial conduct. A contract manufacturing organization (CMO) manufactures the drug or biological product. A contract development and manufacturing organization (CDMO) combines both development and manufacturing under one organisation. Many clinical development programmes involve all three types simultaneously; the CRO manages the trial while a CMO or CDMO manufactures the investigational product.
